Ethos Financial Group LLC Makes New $244,000 Investment in Zoetis Inc. (NYSE:ZTS)

Ethos Financial Group LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 1,235 shares of the company’s stock, valued at approximately $244,000.

A number of other hedge funds have also made changes to their positions in the company. Cary Street Partners Investment Advisory LLC increased its position in shares of Zoetis by 7.4% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock valued at $16,308,000 after acquiring an additional 6,457 shares during the last quarter. Peak Financial Advisors LLC bought a new position in shares of Zoetis during the fourth quarter valued at $2,776,000. Ninety One UK Ltd increased its position in shares of Zoetis by 13.1% during the fourth quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after buying an additional 12,537 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of Zoetis by 10.9% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock valued at $36,230,000 after purchasing an additional 17,976 shares in the last quarter. Finally, GuoLine Advisory Pte Ltd increased its stake in shares of Zoetis by 25.0% in the 4th quarter. GuoLine Advisory Pte Ltd now owns 174,400 shares of the company’s stock valued at $34,421,000 after acquiring an additional 34,900 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on ZTS. Stifel Nicolaus cut their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Barclays reduced their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group decreased their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $211.75.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total value of $159,983.59. Following the sale, the executive vice president now directly owns 15,723 shares in the company, valued at $2,725,267.59. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 2,209 shares of company stock worth $371,293. Insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

ZTS stock traded up $3.21 during midday trading on Thursday, hitting $168.13. The company’s stock had a trading volume of 2,108,446 shares, compared to its average volume of 3,184,266. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The stock has a market cap of $76.72 billion, a price-to-earnings ratio of 32.40, a PEG ratio of 2.57 and a beta of 0.86. The stock’s 50-day moving average price is $166.94 and its 200 day moving average price is $178.83. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.04. The company had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.31 earnings per share. On average, equities analysts forecast that Zoetis Inc. will post 5.77 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.